Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Good to see a bit more coming forward from Oxilio on top of the earlier agreement.
25% increase in the sell price over two days isn’t bad.
Nice to have a positive end to the week, interesting to see two days of concentrated buying, also good to see the mm’s shift upwards which is fairly unusual in nfx without news.
Pump up the volume
"our commercial strategy is to develop Ava 6000 through phase two, we will at some point in phase two be looking more keenly at partnering because if we want to take that into larger studies, phase three studies, then you know we're going to really have to have a partner to do that."
Thanks NFT's, remind me how much you lost again?
Lets clear up a few points.
DG set up LSHS consulting and eventually sold it to Oxilio, as we all know this work was related to OXL001 which is not related in any way to the work Nuformix are doing.
For those who can't read company announcements....
"LSHS is a specialist life science consultancy firm established by Dr Dan Gooding, comprising intellectual property assets relevant to Oxilio’s OXL001 programme. "
Jo Holland is still a consultant to the company, she is invovled in the patent approvals process. Oh look, here she is named in the NXP004 patent application from less than a year ago. I wish I could invent a novel drug formula whilst apparently doing sfa.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US399575356&_cid=P20-LQ2GW8-65203-1
I understand Chab, and obviously there is no such thing as a dead cert, but its more just the strangeness of the mentality of 'this is rubbish and not going anywhere.... so I'm going to try and get something back here'
Just doesn't make sense to me.
I suppose the thing I find hard to square is why, if people think there is little or no chance of success here, they seem to think they will claw back some of their losses here. Surely there are better / higher chances elsewhere if your aim is to regain.
I see it more that the whole direction of travel was knocked sideways firstly by whoever leaked the previous talk rumours etc before selling their shares and not declaring it. Secondly by Dave Tapolczay knowing the Chinese company had hit the rocks and selling before telling the board. Thirdly Anne Brindley coming in and (along with Blackwell) closing the revenue generating aspect of the company. Followed fourthly by Alastair Riddell and Brindley signing up to the disastrous Lanstead deal.
On Oxilio, I'm less fussed, it wasn't / isn't key to the company and the correct thing to do was monetise it for whatever amount, which we will find out shortly. Dans holding in Oxilio is on a par with his holding in NFX.
Ok, so what do you think they should do?
Just fascinated by your process FX, thats all. You're at the stage now where you want the company to fail so that you don't have to blame yourself for losing your money.
What searching questions do you have and why didn't you go and ask them at the AGM?
Have you sold out yet FX?
Xmas money?
NXP001 has not been labelled a key asset for years.
Not worried about websites, they are just to keep small shareholders happy. Management in companies looking to work with others don't spend time looking at websites, they just speak directly to the company.
"It's almost as if they want to keep it secret."
Yep, sometimes companies aren't allowed to talk about what they are doing.
Personally i think the paper is a good thing as it backs up the direction of travel that the company has progressed since March.
If other people are using the same method of testing and publishing it, that can only be a good thing.
Don’t know the finer points of the chemistry, but the paper is about the use of hPCLS, it’s good for NFX that the university that carried out the research identified tranilast as a primary means of exploring this.
"To analyze the effects of anti-fibrotic drugs, we co-treated FC-stimulated hPCLS with the clinically approved anti-fibrotic drug Nintedanib3 (FC+Nintedanib), as well as an N-(2-butoxyphenyl)-3-(phenyl)acrylamide (N23P) derivative of Tranilast (CMP4) which we recently have identified as a novel anti-fibrotic drug candidate"
Interesting article on the use of ex-vivo human precision cut lung slices for the development of treatments for pulmonary fibrosis.
https://www.science.org/doi/10.1126/scitranslmed.adh0908